{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:48:18Z","timestamp":1787788098536,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatric.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.cger.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T02:07:20Z","timestamp":1604282840000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Functional Bowel Disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Aiya","family":"Aboubakr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2020.08.009_bib1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Functional GI and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cger.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2020.08.009_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archinte.163.8.929","article-title":"The economic consequences of irritable bowel syndrome: a us employer perspective","volume":"163","author":"Leong","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2020.08.009_bib5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/gast.2002.32978","article-title":"The burden of selected digestive diseases in the United States","volume":"122","author":"Sandler","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib6","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1111\/j.1572-0241.2001.05258.x","article-title":"Costs of care for irritable bowel syndrome patients in a health maintenance organization","volume":"96","author":"Levy","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.cger.2020.08.009_bib10","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: a systematic review","volume":"97","author":"Saito","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","article-title":"Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time","volume":"109","author":"Agr\u00e9us","year":"1995","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cger.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5056\/jnm.2010.16.2.113","article-title":"Irritable bowel syndrome and co-morbid gastrointestinal and extra-gastrointestinal functional syndromes","volume":"16","author":"Sperber","year":"2010","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1016\/j.cger.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/apt.13746","article-title":"Validity and reliability of the Bristol stool form scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome","volume":"44","author":"Blake","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cger.2020.08.009_bib16","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1572-0241.2003.07542.x","article-title":"Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome","volume":"98","author":"Dunlop","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2009.02.074","article-title":"Postinfectious irritable bowel syndrome","volume":"136","author":"Spiller","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","article-title":"Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome","volume":"47","author":"Spiller","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cger.2020.08.009_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.314.7083.779","article-title":"Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients","volume":"314","author":"Neal","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.cger.2020.08.009_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.44.3.400","article-title":"The role of psychological and biological factors in postinfective gut dysfunction","volume":"44","author":"Gwee","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.cger.2020.08.009_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.51.3.410","article-title":"Prognosis in post-infective irritable bowel syndrome: a six year follow up study","volume":"51","author":"Neal","year":"2002","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cger.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/2050640617731968","article-title":"Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice","volume":"5","author":"Moayyedi","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cger.2020.08.009_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ibd.20059","article-title":"Symptomatic overlap between irritable bowel syndrome and micro- scopic colitis","volume":"13","author":"Limsui","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.cger.2020.08.009_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib25","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cger.2020.08.009_bib27","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cger.2020.08.009_bib28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1756283X17734809","article-title":"An update on prucalopride in the treatment of chronic constipation","volume":"10","author":"Omer","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib29","first-page":"1","article-title":"Tegaserod for the treatment of irritable bowel syndrome","volume":"18","author":"Madia","year":"2019","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.cger.2020.08.009_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ajg.2013.63","article-title":"Fiber and functional gastrointestinal disorders","volume":"108","author":"Eswaran","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/CEG.S167031","article-title":"Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin","volume":"11","author":"Chang","year":"2018","journal-title":"Clin Exp Gastroenterol"},{"issue":"suppl 1","key":"10.1016\/j.cger.2020.08.009_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: potential mechanisms of action of rifaxamin in the management of irritable bowel syndrome with diarrhoea","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cger.2020.08.009_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cger.2020.08.009_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2020.08.009_bib37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1517\/14656566.4.11.2089","article-title":"Alosetron and irritable bowel syndrome","volume":"4","author":"Mayer","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cger.2020.08.009_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1572-0241.2003.07418.x","article-title":"Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride","volume":"98","author":"Miller","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13227","article-title":"Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea","volume":"42","author":"Slattery","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cger.2020.08.009_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cgh.2019.08.062","article-title":"Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea","volume":"18","author":"Sadowski","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.cger.2020.08.009_bib42","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3748\/wjg.v20.i20.6031","article-title":"Role of antispasmodics in the treatment of irritable bowel syndrome","volume":"20","author":"Annah\u00e1zi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cger.2020.08.009_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar","year":"2019","journal-title":"BMC Complement Altern Med"},{"issue":"2","key":"10.1016\/j.cger.2020.08.009_bib44","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A\u00a0novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cger.2020.08.009_bib45","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome foundation working team report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cger.2020.08.009_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ajg.2016.12","article-title":"Food: the main course to wellness and illness in patients with irritable bowel syndrome","volume":"111","author":"Chey","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cger.2020.08.009_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A\u00a0diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cger.2020.08.009_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1440-1746.2009.06149.x","article-title":"Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach","volume":"25","author":"Gibson","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cger.2020.08.009_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jhn.12530","article-title":"The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice","volume":"31","author":"Whelan","year":"2018","journal-title":"J\u00a0Hum Nutr Diet"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069020300653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069020300653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:57:03Z","timestamp":1760061423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069020300653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0749069020300653"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2020.08.009","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}